In recent years, significant progress has been made in the use of high-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell support in the treatment of haematological malignancies and, to a lesser extent, solid tumours. HDC can no longer be described as a recent innovation. The first randomised study was reported in 1987 [1] and the first international consensus conference took place in Lyon, France in 1993 [2] . The prominent publicity given to the initial promising reports of the efficacy of HDC resulted in rapid acceptance and demand for the technique, and consequently little enthusiasm for enrolment in randomised studies. This lack of rigorous scientific assessment has resulted in confusion regarding the position of HDC in the treatment of solid tumours and a number of key questions remain.
The European Solid Tumour Dose Intensification and Cellular Therapy Group (ESTIC) has been established to create a forum that allows the debate of such controversial issues, facilitates the dissemination and critical review of objectively reported data, and assists the exchange of novel and creative ideas. ESTIC will provide a 'think tank' that will allow the thorough debate of such challenging issues and aid the clear positioning of dosage intensification and cellular therapies within the clinical armamentarium. The first ESTIC workshop was held in Sitges, Barcelona, Spain, on 24-25 April 1999, with the challenge of evaluating the current status of chemotherapy dose intensification and cellular therapies in the treatment of solid tumours. One of the most challenging issues discussed during the workshop was the place of HDC for breast cancer particularly in the context of the recent data presented at the ASCO Meeting. We summarised here the ESTIC position regarding this therapeutic strategy.
Women with metastatic breast cancer have a uniformly poor prognosis, with only anecdotal patients achieving prolonged remissions which are durable beyond five years. Similarly, despite the advances which have been made in the adjuvant chemotherapy of high risk, node positive, earlier stage breast cancer, these patients still have a poor prognosis with standard therapy. Indeed, it can be argued that there is no uniformly accepted standard treatment for patients with these conditions, and they have been, and continue to be, the subject of vigorous clinical research. One of the investigational areas which has attracted the greatest interest in recent years has been the use of very high doses of chemotherapy with haematopoietic autograft support. In single arm and historically-controlled studies, high-dose chemotherapy has produced the highest rates of complete remission yet reported for disseminated disease, with, provocatively, an unusually high percentage of these remissions remaining durable at five years. Similarly in high-risk stage II-III disease, striking rates of longterm disease-free survival have been reported.
It has long been realised by investigators studying the field of high-dose chemotherapy in breast cancer, that only the mature results of large-scale prospective random assignment trials could determine the relative merits of this form of therapy in comparison to other modalities, in the treatment of both metastatic and highrisk early stage breast cancer. The highly promising results which this treatment has produced in single arm studies in these settings, together with the widespread, and precipitate diffusion of this expensive, and potentially toxic technology, into routine clinical practice, emphasised the necessity for confirmatory data from randomised trials.
Results have now been published or presented from nine such prospective controlled trials. Mature results from two of the studies, both conducted by Bezwoda and colleagues (one in metastatic disease, one in the high-risk adjutant setting) [3, 4] are unambiguously positive, indicating benefit for high-dose therapy compared to conventionally-dosed chemotherapy. A third study, conducted by Peters et al. [5] , in patients with metastatic breast cancer, indicated that high-dose chemotherapy statistically significantly prolonged the duration of remission of patients who were already in complete remission following conventional chemotherapy, as compared to a policy of observation. In this study, however, patients who were randomised to observation, received high-dose chemotherapy as a form of salvage treatment at the time of relapse. Somewhat surprisingly, this late salvage high-dose chemotherapy resulted in a statistically significantly improved overall survival for patients randomised to observation following complete remission. The study by the PEGASE group in metastatic breast cancer revealed a highly statistically significantly prolonged duration of remission, with no difference in overall survival [6] . At five years, the difference in disease-free survival also disappeared.
Stadtmauer et al. [7] randomised patients who were in ongoing response from prior conventionally dosed chemotherapy to receive high-dose chemotherapy or conventional chemotherapy. Again no difference in diseasefree or overall survival was observed.
Four other studies which addressed the issue of highdose chemotherapy in the adjuvant treatment of highrisk node positive breast cancer have all been negative. Studies by Hortobagyi et al. [8] and Rodenhuis et al. [9] were both very small, each randomising fewer than 90 patients. In the study of the Scandinavian Breast Cancer Study Group [10], patients were randomised to receive nine cycles of intensive epirubicin-containing chemotherapy, the dose of which was tailored to their blood count results, or, to receive four cycles of similar chemotherapy followed by a single high-dose procedure. This study was negative in the sense that it showed only that tailored FEC was superior to a single late intensification. It must be noted that in this study patients on the 'high-dose' arm received substantially less anthracycline and cyclophosphamide than did patients on the 'lowdose' arm. Very preliminary results have also been released from the study of Peters et al. [11] , in which patients with at least ten axillary lymph nodes involved with metastases, were randomised to receive either a higher, or intermediate dose of cisplatin, BCNU and cyclophosphamide as consolidation following four cycles of CAF chemotherapy. At a median follow-up of 27 months, there is no statistically significant difference in disease free or overall survival. It is worth noting, in this regard, that a treatment-related mortality rate of 8% was reported for the high-dose arm, which was related to the experience of the centre and has been improved now that peripheral blood progenitor cells are used as hematopoietic support.
Other advantages may be associated with high-dose therapy, namely, a shorter duration of treatment, and as a result, a more rapid return to a normal quality of life. This may be of relevance in the event that further studies demonstrate equivalent results.
It must also be restated at this time, that the great balance of the evidence to date suggests that high-dose chemotherapy is the most active treatment (in terms of producing responses) which is currently available for metastatic breast cancer. It may be that future investigational efforts will have to focus on defining the optimal use of this modality of treatment. Specifically, it is striking that both of the positive studies which have been reported to date, involve the approach of primary, multi-cycle, high-dose chemotherapy, whereas all seven of the studies which have produced either negative, or ambiguous results, have addressed the strategy of late intensification high-dose chemotherapy, following relatively lengthy phases of standard dose treatment [12] . In addition, other modalities of treatment will be applied following high-dose chemotherapy. Strategies such as immunotherapy or anti-angiogenic drugs may consolidate or improve the response rate obtained by intensive chemotherapy.
In summary, it is apparent that the relative merit of high-dose chemotherapy vis-a-vis conventionally dosed chemotherapy as a treatment for both high-risk early stage, and overtly metastatic breast cancer, is as yet undetermined. 
